Niche-targeted therapy via YAP/TAZ activation enhances hematopoietic regeneration

S Shun Uemura (The Institute of Medical Science, The University of Tokyo, Tokyo, Japan) M Masayuki Yamashita T Takako Yokomizo-Nakano (1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan) A Ayako Aihara (Nissan Chemical Corp., Shiraoka, Japan) T Takumi Iwawaki (Nissan Chemical Industries, LTD., Shiraoka, Japan) S Shuhei Koide Y Yaeko Nakajima-Takagi M Motohiko Oshima Y Yoshiki Omatsu (World Premier International Research Center Initiative Immunology Frontier Research Center, The University of Osaka) Y Yuki Matsumoto Y Yoshiaki Kubota (Department of Anatomy, Keio University School of Medicine) B Bahityar Rahmutulla A Atsushi Kaneda M Miki Nishio (Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine) A Akira Suzuki (Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine) T Takashi Nagasawa (World Premier International Research Center Initiative Immunology Frontier Research Center, The University of Osaka) K Kenta Kagaya (Nissan Chemical Industries, LTD., Shiraoka, Japan) T Taito Nishino (Nissan Chemical Corporation, Tokyo, Japan) A Atsushi Iwama

Abstract

The distinctive milieu of the bone marrow (BM), known as the BM niche, supports hematopoietic stem cells (HSCs) and serves as a foundation for hematopoietic regeneration. Myeloablative stress disrupts not only hematopoietic stem and progenitor cells but also essential BM niche components, including endothelial cells (ECs) and mesenchymal stromal cells (MSCs); disruption of the latter impairs efficient hematopoietic recovery. However, therapeutic strategies targeting niche restoration remain largely underdeveloped. Here, we demonstrate that the Hippo pathway effectors YAP/TAZ are critical for enabling ECs and MSCs to respond to BM injury, and that YAP/TAZ activation accelerates BM niche recovery, thereby promoting hematopoietic regeneration. We found that YAP/TAZ are rapidly activated in both MSCs and ECs following myeloablative stress, maintaining MSC multipotency and orchestrating vascular remodeling. Mechanistically, YAP/TAZ function as transcriptional hubs in MSCs, regulating key transcriptional factors such as Ebf1 and Ebf3. This regulation preserves MSC identity by preventing osteogenic and fibrogenic differentiation while promoting the expression of hematopoietic factors such as Cxcl12 and angiogenic factors. In addition, YAP/TAZ signaling in MSCs and ECs appeared to coordinately remodel sinusoidal vessels following BM injury. These YAP/TAZ-mediated niche responses are essential for HSC retention and hematopoietic regeneration following diverse myelosuppressive therapies. Notably, pharmacological activation of YAP/TAZ enhances BM niche reorganization and augments hematopoietic regeneration following myeloablative therapies. These findings establish YAP/TAZ as central regulators of BM niche resilience, providing a rationale for niche-targeted therapeutic strategies to enhance hematopoietic regeneration.

Article Details

Journal Blood
Volume / Issue Vol. 1, Issue 1
Published June 22, 2026
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (19)

S

Shun Uemura

The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

M

Masayuki Yamashita

T

Takako Yokomizo-Nakano

1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

A

Ayako Aihara

Nissan Chemical Corp., Shiraoka, Japan

T

Takumi Iwawaki

Nissan Chemical Industries, LTD., Shiraoka, Japan

S

Shuhei Koide

Y

Yaeko Nakajima-Takagi

M

Motohiko Oshima

Y

Yoshiki Omatsu

World Premier International Research Center Initiative Immunology Frontier Research Center, The University of Osaka

Y

Yuki Matsumoto

Y

Yoshiaki Kubota

Department of Anatomy, Keio University School of Medicine

B

Bahityar Rahmutulla

A

Atsushi Kaneda

M

Miki Nishio

Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine

A

Akira Suzuki

Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine

T

Takashi Nagasawa

World Premier International Research Center Initiative Immunology Frontier Research Center, The University of Osaka

K

Kenta Kagaya

Nissan Chemical Industries, LTD., Shiraoka, Japan

T

Taito Nishino

Nissan Chemical Corporation, Tokyo, Japan

A

Atsushi Iwama